Medical management of benign prostatic hyperplasia.
The management of benign prostatic hyperplasia has undergone a rapid evolution over the past decade from a surgical emphasis to a medical emphasis. Great strides in the development of alpha-adrenergic blockers, 5 alpha-reductase inhibitors and a variety of phytotherapeutics have fueled this evolution. This article reviews the past, present and future of the medical management of benign prostatic hyperplasia.
Chacon
A
A
Division of Urology, University of California, San Diego, USA.
Monga
M
M
D000317:Adrenergic alpha-Antagonists / Q000627:therapeutic use; D000726:Androgen Antagonists / Q000627:therapeutic use; D004338:Drug Combinations; D004965:Estrogen Antagonists / Q000627:therapeutic use; D004967:Estrogens / Q000502:physiology; D006801:Humans; D008297:Male; D008517:Phytotherapy; D011470:Prostatic Hyperplasia / Q000188:drug therapy* / Q000503:physiopathology / Q000628:therapy
D000317:Adrenergic alpha-Antagonists; D000726:Androgen Antagonists; D004338:Drug Combinations; D004965:Estrogen Antagonists; D004967:Estrogens